Monday, October 26, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 26, 2026

UPS (UPS) Q4 2024 Earnings Call Transcript

View original at finance.yahoo.com
UPS (UPS) Q4 2024 Earnings Call Transcript Image source: The Motley Fool. Date Thursday, January 30, 2025 at 8:30 a.m. ET Call participants Chief Executive Officer — Carol B…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • UPS was concerned about service deterioration under new USPS operating model

    80% confidence

  • UPS believes it is ahead of competitors in generative AI deployment

    80% confidence

  • The Amazon volume reduction was UPS's decision, not Amazon's request, to take control of UPS's destiny

    80% confidence

  • UPS is growing profit dollars, not just margin

    80% confidence

  • The small package market excluding Amazon will grow in low single digits in 2025

    80% confidence

  • U.S. manufacturing is expected to be positive in Q1 2025 after 7 negative quarters

    80% confidence

  • UPS expects no material financial impact from SurePost insourcing

    80% confidence

  • UPS will expand domestic operating margin in every quarter of 2025

    80% confidence

  • Real exports and industrial production will grow 2% YoY in 2025

    80% confidence

  • UPS is not a company that's shrinking, it's a company that's growing

    80% confidence

  • Global GDP will grow 2.5% in 2025 compared to 2024

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com
UPS (UPS) Q4 2024 Earnings Call Transcript — Source | Via News | ViaNews Market